JOSÉ LUIS
GONZÁLEZ LARRIBA
Catedrático de universidad
Hospital Universitario Virgen del Rocío
Sevilla, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario Virgen del Rocío (20)
2024
-
Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP
Clinical and Translational Oncology
2023
-
Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer
New England Journal of Medicine, Vol. 389, Núm. 6, pp. 504-513
2022
-
Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics
BMC Cancer, Vol. 22, Núm. 1
-
SEOM-GECP-GETTHI Clinical Guidelines for the treatment of patients with thymic epithelial tumours (2021)
Clinical and Translational Oncology, Vol. 24, Núm. 4, pp. 635-645
2021
2020
2019
-
Lung cancer in Spain: Information from the Thoracic Tumors Registry (TTR study)
Translational Lung Cancer Research, Vol. 8, Núm. 4, pp. 461-475
2018
-
First analysis of patients (p) with stage IV non-small cell lung cancer (NSCLC) of the thoracic tumor registry (RTT) of the Spanish Lung Cancer Group (SLCG)
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii535-viii536
-
Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced ALK-rearranged non-small cell lung cancer
European Respiratory Journal
2017
-
Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib
Scientific Reports, Vol. 7
-
Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy
Clinical and Translational Oncology, Vol. 19, Núm. 2, pp. 219-226
-
Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action
Targeted Oncology, Vol. 12, Núm. 1, pp. 19-35
-
The role of mTOR inhibition as second-line therapy in metastatic renal carcinoma: clinical evidence and current challenges
Expert Review of Anticancer Therapy, Vol. 17, Núm. 3, pp. 217-226
2016
2010
-
Risk assessment model for first-cycle chemotherapy-induced neutropenia in patients with solid tumours
European Journal of Cancer Care, Vol. 19, Núm. 5, pp. 648-655
-
Update from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma: Focus on special populations
Cancer and Metastasis Reviews, Vol. 29, Núm. SUPPL. 1
-
Updated recommendations from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma
Cancer and Metastasis Reviews, Vol. 29, Núm. SUPPL. 1
2009
-
Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-α as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population
Annals of Oncology, Vol. 20, Núm. 11, pp. 1803-1812
-
Screening for epidermal growth factor receptor mutations in lung cancer
New England Journal of Medicine, Vol. 361, Núm. 10, pp. 958-967
2000
-
Cost-effectiveness analysis of interferon as adjuvant therapy in high-risk melanoma patients in Spain
European Journal of Cancer, Vol. 36, Núm. 18, pp. 2344-2352